

## **REMARKS**

### **Status of the Claims**

Claims 1, 2, 5, 6 and 12-19 are present in this application. Claims 3-4 and 7-11 were previously canceled. Claims 1, 5, and 12 are amended to cancel SEQ ID NO: 4. No new matter has been added by way of this amendment. Reconsideration is respectfully requested.

### **Issue under 35 U.S.C. § 112, 1st Paragraph**

Claims 1, 2, 5, 6, and 12-19 remain rejected under 35 U.S.C. § 112, first paragraph, for allegedly lacking enablement. This rejection is respectfully traversed.

Specifically, the Examiner states that the claims will be allowed if Applicants delete any reference to SEQ ID NO: 4, which is a human protein. According to the Examiner, the specification fails to support a transgenic mouse, comprising a transferred recombinant mouse GANP gene encoding and expressing a human protein, wherein said transgenic mouse produces high affinity antibody-producing B cells.

In an effort to expedite prosecution, Applicants have deleted any reference to SEQ ID NO: 4. A Notice of Allowance is respectfully requested.

**CONCLUSION**


In view of the above-described amendments, Applicants believe the instant application is in condition for allowance.

Should there be any outstanding matters that need to be resolved in the present application, the Examiner is respectfully requested to contact Linda T. Parker, Ph.D., Registration No. 46,046, at the telephone number of the undersigned below to conduct an interview in an effort to expedite prosecution in connection with the present application.

If necessary, the Director is hereby authorized in this, concurrent, and future replies to charge any fees required during the pendency of the above-identified application or credit any overpayment to Deposit Account No. 02-2448.

Dated: NOV 08 2010

Respectfully submitted,

By   
Gerald M. Murphy, Jr.  
Registration No. 28977  
BIRCH, STEWART, KOLASCH & BIRCH, LLP  
8110 Gatehouse Road, Suite 100 East  
P.O. Box 747  
Falls Church, VA 22040-0747  
703-205-8000